Trials Sponsors Conditions Drugs Pricing

Conditions

Joint Pains

Outcome Measures

Primary Outcomes (1)

Change in Knee Pain Intensity from End of Supplementation to Race Finish (Visual Analog Scale)
Knee pain is self-assessed using a Visual Analog Scale (VAS, 0-10 cm) at the end of the 30-day supplementation period (T1, day before the race) and immediately at race finish or withdrawal (T2). The primary outcome is the within-participant change in VAS score (T2 minus T1), compared between the curcumin-ginger-piperine (9-5-1) group and the placebo group.
From Day 30 (T1, end of the 30-day supplementation period) to race finish or withdrawal (T2) - up to approximately 60 hours later, corresponding to the maximum allowed race duration.

Secondary Outcomes (11)

Kinetics of Joint Pain Across the Study Period (Ankles, Knees, Hips)
(T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)
Change in Joint Range of Motion (Ankles, Knees, Hips)
Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)
Change in circulating pro-inflammatory and anti-inflammatory cytokines (pg/mL)
Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)
Change in Inflammatory biomarkers (ng/mL)
Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)
Change in serum enzyme activity (U/L)
Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)
+6 more secondary outcomes

Study Arms (2)

9-5-1

EXPERIMENTAL

Dietary Supplement: 9-5-1

Control

PLACEBO COMPARATOR

Dietary Supplement: Placebo

Interventions

9-5-1Dietary supplement

The investigational intervention is an oral food-supplement capsule combining curcumin, ginger, and piperine in a proprietary "9-5-1" ratio (curcuma extract : ginger extract : black pepper/piperine extract), administered as 4 capsules per day for 30 consecutive days prior to the race.

9-5-1

PlaceboDietary supplement

Capsule excipients are maltodextrin and hydroxypropylmethylcellulose (HPMC), allowing an identical-appearing placebo for double-blind conditions.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Registered for "La Diagonale des Fous" (Grand Raid de La Réunion, 175 km, 2026 edition)
Free, informed, signed consent obtained prior to any study-related procedure

Sponsors & Collaborators

Centre Hospitalier Universitaire de la Réunion
Otherlead

Study Sites (1)

Dr Nicolas BOUSCAREN

Saint-Pierre, CHU de La Réunion, 97400, France

RECRUITING

PINARDCONTACT0262353530

CélesteCONTACT

MeSH Terms

Conditions

Arthralgia

Condition Hierarchy (Ancestors)

Joint DiseasesMusculoskeletal DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Nicolas BOUSCAREN, Dr

CONTACT

+33262353530 Nicolas.BOUSCAREN@chu-reunion.fr

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Masking: SINGLE
Who Masked: PARTICIPANT
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

July 2, 2026

First Posted

July 13, 2026

Study Start

September 14, 2026

Actual (reported)

Primary Completion

October 20, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Anti-inflammatory Effects of Curcumin, Ginger and Piperine Supplementation in Ultra-trail Runners: a Double-blind Randomized Placebo-controlled Trial

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (11)

Study Arms (2)

9-5-1

Control

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (11)

Study Arms (2)

9-5-1

Control

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations